LWAC
TXMD icon

Laurel Wealth Advisors (California)’s TherapeuticsMD TXMD Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,861
Closed -$225K – 437
2019
Q4 		$225K Buy
+1,861
New +$268K 0.04% 418

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurel Wealth Advisors (California)'s TXMD Position: Q1 2020 in Review

Laurel Wealth Advisors (California) sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 1,861 shares — an estimated $225K sold.

Laurel Wealth Advisors (California) first reported a position in TXMD in Q4 2019 and held it in 1 quarter. The position peaked at $225K in Q4 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

  • Laurel Wealth Advisors (California) reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
  • Laurel Wealth Advisors (California) sold 1,861 TherapeuticsMD shares in Q1 2020, an estimated $225K.
  • Laurel Wealth Advisors (California) first reported a position in TherapeuticsMD in Q4 2019 and held it in 1 quarter.
  • Laurel Wealth Advisors (California)'s TherapeuticsMD position peaked at $225K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q1 2020, filed 15 May 2020.